MK2206 + Hydroxychloroquine for Advanced Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new combination of drugs for treating advanced cancers such as melanoma, prostate, or kidney cancer. The goal is to determine the optimal dosage and assess how these drugs work together to halt cancer growth. Specifically, the trial combines an Akt inhibitor (MK2206), which blocks enzymes that promote tumor cell growth, with hydroxychloroquine, a chemotherapy drug that kills or prevents the spread of cancer cells. Suitable candidates for this trial have previously undergone other cancer treatments and have advanced solid tumors. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop all current medications, but you cannot be on certain medications that affect the heart's rhythm or those that interact with the trial drugs. If you're on medications that affect the liver enzyme CYP3A4, the trial team will review your case to see if you can switch to other medications.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research has shown that the drug MK2206 has been tested in people with advanced cancers. These studies found that MK2206 is generally safe, though some individuals experienced side effects such as skin rashes and diarrhea. Most participants managed these side effects well.
Hydroxychloroquine is often used alongside other cancer treatments. It has shown promise in fighting cancer by blocking a process that cancer cells use to survive. Some studies have found that long-term use can cause side effects, usually related to the dose. However, short-term use with other drugs has been better tolerated, with fewer side effects.
Overall, these treatments have been tested and are considered safe for clinical trials. It is important to be aware of possible side effects and discuss any concerns with the trial team.12345Why do researchers think this study treatment might be promising?
Researchers are excited about combining the Akt inhibitor MK2206 with hydroxychloroquine for advanced cancers because it targets cancer cells differently from standard treatments. Most current therapies focus on traditional chemotherapy or targeted therapies that inhibit specific proteins. However, MK2206 disrupts the Akt signaling pathway, which is crucial for cancer cell survival and growth. Adding hydroxychloroquine may enhance this effect by interfering with the cancer cells' ability to recycle components, potentially making them more vulnerable to treatment. This combination approach could offer hope for patients with advanced cancers who have limited options.
What evidence suggests that this treatment might be an effective treatment for advanced cancers?
Research has shown that the drug MK2206, which participants in this trial will receive, can help fight cancer by blocking certain proteins that allow tumor cells to grow. It has increased the death of cancer cells and stopped their growth, especially in breast cancer. In this trial, participants will also receive hydroxychloroquine starting in cycle 2. Studies suggest that hydroxychloroquine can be effective in cancer treatment by preventing cancer cells from recycling waste, which they need to survive. It also helps kill cancer cells and stop them from spreading. When used together, these drugs may work better than when used alone, providing a stronger attack on cancer cells.23678
Who Is on the Research Team?
Jyoti Malhotra, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, melanoma, prostate or kidney cancer who have tried at least one standard treatment. They must be able to swallow tablets, not be pregnant or breastfeeding, and agree to use contraception. People with certain eye diseases, uncontrolled diabetes, active infections or heart problems can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Akt inhibitor MK2206 orally on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine orally twice daily on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Akt inhibitor MK2206
- Hydroxychloroquine
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor